Considerations Following Locoregional Therapy in HCC

May 31, 2017

Considerations Following Locoregional Therapy in HCC


May 2015

  • 64-year old obese female presented with fatigue and unexplained weight loss
  • History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
  • Lab results: AFP= 1,500 IU/ml
  • ECOG=1; Child-Pugh A
  • CT revealed 1 large liver mass, right side of liver close to a major blood vessel
  • No extrahepatic disease
  • Liver-directed therapy with DEB-TACE was performed
  • Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
  • Patient had a complete response
  • AFP= 200 IU/ml at follow up

February 2017

  • Follow-up imaging showed progression and evidence of bone metastases
  • Therapy was initiated with sorafenib at 400 mg BID
  • Follow-up testing showed liver decompensation